Economy/Home · Economy

Kolon TissueGene (950160) Stock Treads Water... Focus on Bid for 7th Consecutive Winning Session

Kolon TissueGene (950160) is showing notable volatility on the 18th, fluctuating around the flatline in early trading. As of 9:43 a.m. on the 18th, Kolon TissueGene is trading at 28,600 won, up 50 won (0.18%) from the previous session, hovering near flat as it moves between gains and losses. Intra

Oseong Kwon
Staff Reporter
3 min read
Kolon TissueGene (950160) Stock Treads Water... Focus on Bid for 7th Consecutive Winning Session
CBC News

Kolon TissueGene (950160) is showing notable volatility on the 18th, fluctuating around the flatline in early trading.

As of 9:43 a.m. on the 18th, Kolon TissueGene is trading at 28,600 won, up 50 won (0.18%) from the previous session, hovering near flat as it moves between gains and losses.

Intraday swings were relatively wide. The stock's intraday high reached 29,350 won, but selling pressure later pushed it down to as low as 26,650 won. The gap between the high and low amounted to 2,700 won, and after climbing back near the previous day's close, a fierce tug-of-war continues.

The key point to watch is whether the recent streak of consecutive gains can extend through today. Kolon TissueGene rose for six consecutive trading days from the 7th through the 14th. On the 14th, it closed at 28,550 won, up 11.52% from the previous session, after rising as high as 31,850 won intraday.

As this is the first session after a sharp short-term price move, the afternoon trading trend also warrants attention. With time remaining until the close, it remains to be seen which direction the stock will take. All eyes are on whether Kolon TissueGene, up for six straight sessions, will extend its gains today to achieve a seventh consecutive rise, or pause its winning streak to catch its breath.

[※ This article is not intended as investment advice; the final decision and responsibility for investments rest with the investor.]

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.